Skip to main content

Table 1 Patient characteristics when tacrolimus treatment was started

From: Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

 

Overall (N = 87)

Oral (N = 22)

Intravenous (N = 65)

p value

Female/male

39 (45%)/48 (55%)

8 (36%)/14 (64%)

31 (48%)/34 (52%)

0.46

Age (years)

40 (24–50)

39 (25–49)

40 (24–52)

0.57

Disease duration (years)

2.9 (1.0–8.3)

2.5 (0.8–11.5)

3.0 (1.2–7.8)

0.95

Disease type: extensive /left-sided

71 (82%)/16 (18%)

16 (73%)/6 (27%)

55 (85%)/10 (15%)

0.18

Body mass index

19.4 (16.9–22.6)

20.1 (16.6–23.6)

19.4 (16.8–22.1)

0.8

Lichtiger index

13 (12–15)

12 (12–14)

14 (12–15)

0.09

Endoscopic score (UCEIS)

6 (5–7)

6 (4–8)

6 (5–7)

0.86

Hemoglobin (g/dL)

11.3 (9.7–12.8)

12.0 (10.3–13.4)

11.3 (9.2–12.8)

0.13

Albumin (g/dL)

3.2 (2.6–3.7)

3.2 (2.6–3.8)

3.2 (2.6–3.7)

0.74

C-reactive protein (mg/dL)

3.1 (1.5–9.0)

4.2 (2.2–11.8)

2.8 (1.1–7.4)

0.06

Erythrocyte sedimentation rate (mm/h)

53 (32–81)

56 (31–73)

48 (35–82)

0.87

Creatinine (mg/dL)

0.7 (0.6–0.8)

0.7 (0.6–0.8)

0.7 (0.6–0.8)

0.83

Corticosteroid refractory/dependent

66 (76%) / 21 (24%)

16 (73%) / 6 (27%)

50 (77%) / 15 (23%)

0.45

Biologic agent naive

61 (70%)

14 (64%)

47 (72%)

0.31

  1. Numerical data shows median value with interquartile range. Continuous variables were compared using the Mann–Whitney U test and categorical variables were compared using Fischer’s exact test
  2. UCEIS ulcerative colitis endoscopic index of severity